TY - JOUR
T1 - Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapses
AU - Riva, Eloisa
AU - Oliver, Carolina
AU - Pérez, Maria Del Carmen
AU - Telis, Osmar
AU - Díaz, Lilian
AU - Mikhael, Joseph R.
N1 - Publisher Copyright:
© 2015 Taylor & Francis.
PY - 2016/6/2
Y1 - 2016/6/2
N2 - The standard approach to the follow-up of lymphoma includes computed tomography (CT) every 6-12 months for the first 2 years and, then, as clinically indicated. Recent evidence suggests that most relapses are detected clinically, outside scheduled CT which, on the other hand, increases risk of second malignancies and cost. In early-stage lymphomas, involved site CT instead of full body CT may be a reasonable alternative to reduce radiation dose. We analyzed whether regular CT surveillance detects asymptomatic relapses in a single-center Uruguayan early stage non-Hodgkin lymphoma (NHL) population. We evaluated utility of full body CT halfway and at the end-of-treatment evaluation and calculated the radiation exposure. In our study, CT surveillance added nothing to clinical follow-up. Moreover, 44% of our patients received a cumulative effective dose that doubles the risk of malignancies. Involved-site CT scan would be enough to monitor response during treatment in early stage NHL.
AB - The standard approach to the follow-up of lymphoma includes computed tomography (CT) every 6-12 months for the first 2 years and, then, as clinically indicated. Recent evidence suggests that most relapses are detected clinically, outside scheduled CT which, on the other hand, increases risk of second malignancies and cost. In early-stage lymphomas, involved site CT instead of full body CT may be a reasonable alternative to reduce radiation dose. We analyzed whether regular CT surveillance detects asymptomatic relapses in a single-center Uruguayan early stage non-Hodgkin lymphoma (NHL) population. We evaluated utility of full body CT halfway and at the end-of-treatment evaluation and calculated the radiation exposure. In our study, CT surveillance added nothing to clinical follow-up. Moreover, 44% of our patients received a cumulative effective dose that doubles the risk of malignancies. Involved-site CT scan would be enough to monitor response during treatment in early stage NHL.
KW - Lymphoma and Hodgkin disease
KW - prognostication
KW - radiation
UR - http://www.scopus.com/inward/record.url?scp=84945206030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945206030&partnerID=8YFLogxK
U2 - 10.3109/10428194.2015.1094694
DO - 10.3109/10428194.2015.1094694
M3 - Article
C2 - 26374395
AN - SCOPUS:84945206030
SN - 1042-8194
VL - 57
SP - 1363
EP - 1366
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -